Skip to main content
GoodMoatv1.3
Sign in
VIR logo

VIR

CompareEarnings: Aug 31, 2026

Vir Biotechnology Inc

Exchange: NASDAQSector: HealthcareIndustry: Biotechnology

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers iii across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Footnotes: i Huo, Xingyue et al. "Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram." Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.3233/SHTI250070 ii 50% premium to the 30 day volume weighted average share price as of February 19, 2026 iii Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

Current Price

$8.79

-3.30%
Profile
Valuation (TTM)
Market Cap$1.23B
P/E-2.77
EV—
P/B1.60
Shares Out139.52M
P/Sales18.72
Revenue$65.50M
EV/EBITDA—

Vir Biotechnology Inc (VIR) Company Profile

VIR Company Information

Vir Biotechnology, Inc.

is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer.

Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers iii across validated targets in solid tumor indications.

Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies.

Vir Biotechnology routinely posts information that may be important to investors on its website. Footnotes: i Huo, Xingyue et al.

"Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram. " Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.

3233/SHTI250070 ii 50% premium to the 30 day volume weighted average share price as of February 19, 2026 iii Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease.

PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc. , a Sanofi company.

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

California, USA

VIR Key Officers

Key officers data coming soon

VIR Company Profile

Vir Biotechnology Inc (VIR) is a Healthcare company in the Biotechnology industry. It trades on NASDAQ. The company is based in California, USA.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers iii across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. Footnotes: i Huo, Xingyue et al. "Predicting Survival in Metastatic Castration-Resistant Prostate Cancer Patients: Development of a Prognostic Nomogram." Studies in health technology and informatics vol. 323 (2025): 164-168. doi:10.3233/SHTI250070 ii 50% premium to the 30 day volume weighted average share price as of February 19, 2026 iii Vir Biotechnology retains exclusive rights to the PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

Market cap is $1.23B. There are 139.5M shares outstanding.

See the full Vir Biotechnology Inc profile on GoodMoat. It covers key officers, financial metrics, and sector details. You can also use GoodMoat's DCF calculator, fair value models, and quality score to help decide if VIR is a good investment.